Insights
Search Results
Client Highlights
1.09.26
Firm Advises Frazier Life Sciences on Patent Matters Related to AirNexis Therapeutics’ $200 Million Series A Financing
On January 9, 2026, AirNexis Therapeutics, a clinical-stage biotech company developing therapeutics for pulmonary diseases, announced the closing of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The financing was led by founder Frazier Life Sciences, with participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital, and Enavate Sciences, among others.
Client Highlights
11.25.25
Wilson Sonsini Advises AXA IM Alts on Patent Matters Related to Imbria Pharmaceuticals’ Upsized Series B Financing
On November 17, 2025, Imbria Pharmaceuticals, a clinical-stage company developing transformational cardiovascular disease therapeutics, announced the participation of AXA IM Alts in an upsized Series B financing. With this investment, AXA IM Alts joins a leading investor syndicate that includes RA Capital, SV Health Investors, Deep Track Capital, AN Ventures, Catalio Capital Management, and Cytokinetics. Wilson Sonsini Goodrich & Rosati advised AXA IM Alts on patent matters related to the transaction.
Client Highlights
10.09.25
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals
On October 8, 2025, ARS Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced the Opposition Division of the European Patent Office (EPO) upheld the validity of all claims in EP 3678649, a patent validated in over 30 European countries related to neffy® (epinephrine nasal spray). ARS Pharma’s issued global intellectual property portfolio related to neffy provides coverage until at least 2039.
Client Highlights
10.08.25
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million
On September 29, 2025, ARS Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced it has entered into a senior secured term loan facility of up to $250 million with an affiliate of RA Capital Management, the company’s largest shareholder, and an affiliate of OMERS Life Sciences as lenders. Wilson Sonsini Goodrich & Rosati advised ARS Pharma on patent matters related to the transaction.
7.29.24
Firm Advises Nerio on IP Matters Related to $1.3 Billion Acquisition by Boehringer
On July 29, 2024, biopharmaceutical company Boehringer Ingelheim announced its acquisition of Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, and its preclinical program of novel immune checkpoint inhibitors for up to $1.3 billion. Wilson Sonsini Goodrich & Rosati advised Nerio Therapeutics on IP related to the transaction and advises the company on patent matters.
Client Highlights
7.02.24
Firm Advises Radionetics on Patent Matters Related to Strategic Agreement with Eli Lilly
On July 1, 2024, Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals to treat a broad range of solid tumors, announced the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Wilson Sonsini Goodrich & Rosati has been primary patent counsel for Radionetics Oncology and advised the company on patent matters related to the transaction.
Client Highlights
4.03.24
Wilson Sonsini Advises Alterome on $132 Million Series B
On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.
Client Highlights
3.01.24
Wilson Sonsini Advises vTv Therapeutics on Patent Matters Related to $51 Million Private Placement Financing
On February 28, 2024, vTv Therapeutics, a clinical-stage biopharmaceutical company, announced that it successfully closed a private placement financing (PIPE) to healthcare-focused institutional investors. Total gross proceeds of the PIPE were $51 million. Wilson Sonsini Goodrich & Rosati advised vTv Therapeutics on patent matters related to the transaction.
Client Highlights
1.03.24
Wilson Sonsini Advises Radionetics Oncology on IP Matters Related to $52.5 Million Series A
On January 3, 2024, San Diego-based Radionetics Oncology, a clinical stage radiopharmaceutical company, announced that it has raised $52.5 million in Series A fundraising led by Frazier Life Sciences, 5AM Ventures, and new investor, DCVC Bio, with participation from Crinetics Pharmaceuticals, and GordonMD Global Investments. Wilson Sonsini Goodrich & Rosati advised Radionetics Oncology on IP matters related to the transaction.